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Doxorubicin (DOX) causes long-term cardiomyopathy that is dependent on oxidative stress and contractility disorders.
Tirapazamine (TP), an experimental adjuvant drug, passes the same red-ox transformation as DOX. The aim of the study was
to evaluate an eﬀect of tirapazamine on oxidative stress, contractile protein level, and cardiomyocyte necrosis in rats administered
doxorubicin. Rats were intraperitoneally injected six times once a week with tirapazamine in two doses, 5 (5TP) and 10mg/kg
(10TP),whiledoxorubicinwasadministeredindose1.8mg/kg(DOX).Subsequenttwogroupsreceivedbothdrugssimultaneously
(5TP+DOX and 10TP+DOX). Tirapazamine reduced heart lipid peroxidation and normalised RyR2 protein level altered by
doxorubicin. There were no signiﬁcant changes in GSH/GSSG ratio, total glutathione, cTnI, AST, and SERCA2 level between
DOX and TP+DOX groups. Cardiomyocyte necrosis was observed in groups 10TP and 10TP+DOX.
1.Introduction
Doxorubicin(DOX)isaveryeﬃcientantitumordrug,butits
use is limited by a dose-dependent, irreversible, and progres-
sive cardiomyopathy, which may become evident years after
completion of therapy [1–5]. The main pathomechanism
of cardiotoxicity is connected with oxidative stress and
disorders in function of contractile proteins, which are at
least partly related to oxidative stress [6–10], and thus we
assumed that any agent causing changes in red-ox balance
may have an inﬂuence on DOX-related cardiotoxic eﬀects.
Tirapazamine (TP), designed especially for eradicating
hypoxic tumor cells, which are commonly resistant to classi-
cal radio- and chemotherapy [11, 12], passes the same red-
ox metabolic changes as DOX. The drug has a moderate
antitumor activity [13, 14]b u t ,a si th a sb e e np r o v e di n
many experimental studies, in combination with classical
chemotherapeutics and radiotherapy it can increase the anti-
cancer eﬀectiveness compared to the treatment with classical
chemotherapeutics alone [15–17] and thus giving hope for it
to be used as an adjuvant.
Moreover both drugs TP and DOX pass similar red-
ox-related metabolic transformations (Figure 1). These
metabolic pathways of TP in normoxic conditions and DOX
are related to one-electron reduction with the formation of
radicals, TP∗ or DOX∗ respectively [18, 19]. Many NADPH
and NADH-dependent enzymes catalyzing that reaction are
commonforDOXandTP,forexample,NADPHcytochrome
P450 reductase [16, 20], NOS [21–24], NADPH oxidase [25–
27], and catalase [28, 29]. In the next step, TP∗ and DOX∗
are reoxygenated to a nonradical parent compound and at
the same time a superoxide radical is formed (O2
•−). This2 Oxidative Medicine and Cellular Longevity
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Figure 1: Schematic presentation of one-electron reduction of
DOX and TP in hypoxic and normoxic conditions. Independent of
hypoxia or normoxia, both DOX and TP go through one-electron
reduction catalyzed by NADH dehydrogenase, xanthine oxidase,
NOS and NADPH cytochrome P-450 reductase. In normoxic
conditions DOX and TP radicals transfer one electron to oxygen
and transform back to their parent compounds. However, in
hypoxia, TP radical preferentially destroys DNA.
cycle of reactions may repeat many times leading to an
overproduction of O2
•−, which may be a source of hydrogen
peroxide and the much more toxic hydroxyl radical [10].
These reactive oxygen species (ROS) are responsible for the
oxidative stress.
It has been evidenced that some ROS-dependent car-
diotoxic eﬀects are also observed after DOX administration
[30–32]. Among them are disorders in Ca2+ intracellular bal-
ance [33], mitochondrial dysfunction [34], cardiomyocytes
death [35], and heart remodeling [36], ultimately leading to
disturbance in contractility and heart failure [1, 2, 33]. ROS-
related disorders in Ca2+ intracellular balance resulting in
cardiac contractility disturbance are partly related to post-
transcriptional regulation of RyR2 and SERCA2 [7, 9, 37–
39]. Transcriptional regulation of both proteins, mediated by
DOX, has also been found [40, 41].
Summarizing,DOXandTPareinvolvedinthesametype
of one-electron reduction resulting in ROS overproduction.
In the light of ROS-dependent mechanisms responsible for
cardiotoxicity, it is possible that TP will change the response
of cardiomyocytes to DOX. Therefore, if there is an inter-
action between the two drugs, it might be of clinical impor-
tance.TheaimofthestudywastoevaluatetheeﬀectofTPon
oxidativestress,contractileproteinlevel,andcardiomyocytes
necrosis in rats administered DOX.
2.MaterialsandMethods
2.1. Animals and Treatment. T h ee x p e r i m e n t a lp r o t o c o lw a s
approved by the Local Bioethical Committee of the Medical
University in Lublin. The study was conducted on sexually
mature male albino rats of Wistar CRL: (WI)WUBR strain,
obtained from a commercial breeder (Warsaw-Rembertow,
Poland). Animals with the initial body weight of 160–195g
were maintained in stable conditions at 22◦Cw i t ha1 2 h
light/dark cycle and given standardized granulated fodder
LSM (AGROPOL, Poland). The rats were intraperitoneally
(i.p.) exposed to doxorubicin (DOX; Ebewe, Austria) and/or
tirapazamine (TP; International Laboratory, USA).
The animals were randomly divided into six groups (n =
7):DOX:doxorubicin1.8mg/kg;5TP:tirapazamine5mg/kg;
10TP: tirapazamine 10mg/kg; 5TP+DOX: 1.8mg/kg dox-
orubicin and 5mg/kg tirapazamine; 10TP+DOX: 1.8mg/kg
doxorubicin and 10mg/kg tirapazamine; control was given
i.p. 0.9% NaCl solution. Doxorubicin (1.8mg/kg) and tira-
pazamine in both doses were intraperitoneally injected once
a week for six weeks in all study groups. A week after admin-
istration of both compounds the study was terminated. The
animalsweresacriﬁcedandthebloodandheartsampleswere
collected during autopsy.
Theheartwaswashedwith20mLofsalinethensectioned
along the interventricular and coronal grove. The wall of
the left ventricle was placed in liquid nitrogen and stored at
−75◦C until the time of biochemical and molecular analysis.
The right ventricular wall sample was ﬁxed in buﬀered 10%
formalin and histologically processed.
2.2. Determination of Serum Biochemical Parameters. Heart
cTnI (commercial kits Life Diagnostic, USA) concentration
in rat serum was assessed with ELISA where two types of
antibodies were used in the determination: antibodies cov-
ering microtiter plate and secondary antibodies bound to
horseradish peroxidase. The product of enzymatic reaction
was spectrophotometrically detected at 450nm.
Aspartate aminotransferase (AST) activity was deter-
mined by the kinetic method with commercial diagnostic
kits (Cormay, Poland) where the transfer of amino group
between L-aspartate and 2-oxoglutarate was catalyzed by
AST and the decrease in NADH absorbance was measured
at 340nm.
2.3. Determination of Tissue Markers for Red-Ox Imbalance.
Allmeasurementswereconductedonhomogenatesobtained
from ∼20mg of frozen cardiac samples using the extraction
buﬀer provided by the manufacturer of each commercial kit.
The evaluation of lipid peroxidation in cardiac homoge-
nates was based on malondialdehyde and 4-hydroxyalkenals
concentration (MDA+4HAE). The commercial kit Biotech
LPO-586forMDA+4HAE(OxisResearch,USA)wasusedfor
the assessment. The concept of the method is based on the
reaction between MDA and 4HAE with N-methyl-2-phenyl-
indol. After mixing N-methyl-2-phenylindole and methanol
with the supernatant acquired from the homogenization,
methanesulfonic acid was added and all reagents were placed
in temperature 45◦C for 60 minutes. Next, the solution
was centrifuged and the supernatant containing the product
was transferred to the plastic plate used in the spectropho-
tometric reader PowerWave XS (BioTek USA) at 586nm.
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the manufacture description and the concentration of
MDA+4HNE in tested samples was calculated from formula
of calibration curve y = 0.0896x − 0.008. The obtained
date was calculated taking into account recommendations
described in the procedure. Obtained results were expressed
in nmol/g cardiac sample.
NADPH and NADH concentrations were determined by
thecomparablespectrophotometricmethoddescribedinthe
commercial kit (Bio Vision, USA). The cardiac homogenate
was incubated at 60◦C in order to decompose NADP
particles. Final readings were made using PowerWave XS
Microplate Spectrophotometer (Bio-Tek, USA) at 450nm.
Glutathione determination was conducted using com-
mercialkitGSH/GSSG-412(OxisResearch,USA).Thefrozen
cardiac samples (∼20mg) were homogenized in extraction
buﬀer provided by the manufacturer. Total glutathione
(GSHt; GSH+GSSG) was determined in the enzymatic reac-
tion, where Ellman’s reagent (5,5 -dithio-bis-2-nitrobenzoic
acid) reacts with GSH forming color product with the
maximum of absorbance at 412nm. The concentrations of
GSH and GSSG and GSH/GSSG ratio were assessed after
measuring the speed of the reaction and establishing the
calibrations curves. The concentrations of GSH and GSSG
were determined based on calibration curve described by the
formula y = 0.1447x+0.0004 and y = 0.1476x. On the basis
of the obtained date the GSH/GSSG ratio was calculated.
2.4. Determination of DNA Oxidative Damage. Commercial
kit (Fermentas, Lithuania) was used for the isolation of
cardiac DNA according to the manufacturer manual. Frozen
tissue was pulverized in liquid nitrogen and suspended in
TRIS-EDTA (TE) buﬀer. Then, the sample was incubated in
lysis buﬀer at 65◦C. Released DNA was extracted with the
use of chloroform and then precipitated with precipitation
factor.
DNA oxidative damage in cardiac muscle was evaluated
by measuring the amount of basic sites (so-called AP) with
commercial kit (Dojindo, Japan). Isolated DNA was labeled
withARPreagent,whichcanrecognizealdehydegroupofthe
open ring in AP sites and can combine with biotin. Then,
biotin-avidin-speciﬁc connection and horseradish peroxi-
dase were used for the colorimetric detection at 650nm.
2.5. Determination of SERCA2 and RyR2 Proteins Level. Tis-
sue samples were homogenized in 20mM phosphate buﬀer
(pH 7.4; proportions: 0.5g of tissue and 2cm3 of buﬀer)
with a protease inhibitor cocktail (Sigma-Aldrich, USA) in
a homogenizer with a Teﬂon piston (5 minutes at 4000rpm).
Then, homogenates were centrifuged at 14000rpm at 4◦C
for 20 minutes and used to quantify SERCA2 and RyR2
proteinsbyimmunoblotting.Fiverandomlyselectedsamples
were taken from diﬀerent randomly selected animals in
each study group. 20μgo fp r o t e i nw a sl o a d e di nap o l y -
acrylamide gel, and a 50-minute electrophoretic separation
was performed under reducing conditions in XCellSureLock
apparatus (Invitrogen, USA) at constant voltage of 200V.
After separation, the gel and nitrocellulose membrane were
placed between two layers of ﬁlter paper and put between
two electrodes of XCell II Blot Module electrotransfer
apparatus (Invitrogen, USA). The transfer was conducted
for 60 minutes at a constant voltage of 30V. The blots were
developed using Western Breeze Chromogenic Detection Kit
(Invitrogen, USA). Nonspeciﬁc antibody-binding sites were
blocked, and the membrane was incubated in the solution of
a primary antibody: monoclonal mouse antibody against rat
SERCA2 protein (clone 2A7-A1; Aﬃnity BioReagents, USA)
or against rat RyR2 protein (clone 34C; Aﬃnity BioReagents,
USA). After washing, the membrane was incubated with
thesecondaryantibodycombinedwithalkalinephosphatase.
The last step was to mark the sites of reaction with antigen
by the reaction of alkaline phosphatase and chromogen. The
relative intensities of the bands were quantiﬁed using the 1D
Image Analysis Software program (Kodak, USA), and all the
values were normalized to the intensities of the respective
beta-actin signal that was used as a loading control (Abcam,
USA).
2.6. Preparation of Slides for Histological Evaluation. 4μm
histological slides obtained from paraﬃn blocks were rou-
tinely processed and stained with hematoxylin and eosin
(H&E). Selye’s method was also used to visualize cardiomy-
ocyte necrosis.
2.7. Statistical Analysis. The obtained data was expressed as
mean ± SD and statistically analyzed by STATISTICA 5.0
software. Continuous data were compared among exper-
imental groups using the Kolmogorov-Smirnov test. The
statistical signiﬁcance of diﬀerences between control and
study groups was evaluated by Student’s t-test or U Mann-
Whitney test. Group-to-group comparisons were made by
one-way ANOVA. A value of P<0.05 was considered as
statistically signiﬁcant.
3. Results
3.1. Markers of Oxidative Stress. Levels of MDA+4HNE
were signiﬁcantly higher in all study groups compared to
control (Table 1). However they were signiﬁcantly lower
in group 10TP+DOX compared to DOX. Since the change
in marker of lipid peroxidation was mostly pronounced in
the groups receiving higher dose of TP with DOX, markers
of DNA oxidative damage were measured in these groups:
levels of oxidative DNA damage were higher in groups
receiving DOX and 10TP+DOX compared to control but
there was no signiﬁcant diﬀerence between these two groups
(Figure 5). Level of NADPH (Table 1) was signiﬁcantly
higher in group 10TP+DOX compared to both control and
DOX group, while level of total glutathione was signiﬁcantly
elevated in the group treated only with doxorubicin when
compared to control. The GSH/GSSG ratio was elevated in
all study groups compared to control. However, there were
no signiﬁcant diﬀerences when compared to DOX. NADH
level was signiﬁcantly decreased in group 5TP compared to
control but increased in 10TP+DOX compared to the DOX
group. Together, it was stated that DOX and TP increased
levels of markers involved in oxidative stress. However,4 Oxidative Medicine and Cellular Longevity
Table 1: Markers of oxidative stress (heart homogenates).
n MDA+4HAE (nmol/g) NADPH (ng/g) NADH (ng/g) GSHt (nmol/g) GSH/GSSG
Control 7 37.45 ±6.75 17.04 ±3.94 28.08 ±8.66 742.71 ±148.62 16.96 ±5.46
DOX 7 164.07 ±103.78a 18.67 ±2.98 21.66 ±6.01 962.45 ± 134.73a 38.70 ± 16.85a
5TP+DOX 7 114.66 ± 68.42a 27.87 ±15.39 27.21 ±4.85 824.52 ±122.94 37.67 ± 6.01a
10TP+DOX 7 59.90 ± 16.05a,b 30.42 ± 12.74a,b 42.5 ± 15.5b 891.62 ±178.11 38.96 ± 8.13a
5TP 7 68.70 ± 13.60a 15.23 ±2.35 15.76 ± 4.57a 857.00 ±128.46 38.12 ± 9.08a
10TP 7 62.88 ± 13.73a 15.83 ±2.16 21.24 ±3.55 891.62 ±178.11 38.11 ± 3.13a
aP < 0.05 versus control, bP < 0.05 versus DOX.
among all these tested parameters, the statistical signiﬁcance
between DOX versus 10TP+DOX was the only observed
referring to lipid peroxidation marker.
3.2. Light Microscopy Evaluation of the Myocardium. The
morphological evaluation of hearts in the DOX group did
not reveal signs of necrosis, neither in H&E nor in Selye’s
staining, speciﬁc for necrosis. In contrast, signs of car-
diomyocyte necrosis were found in 10TP and 10TP+DOX
and conﬁrmed in both aforementioned stainings (Figures
2(a) and 2(b)). Low-intensity inﬂammatory inﬁltration was
observed near necrotic foci.
3.3. Plasma Concentrations of cTnI and AST Plasma Activity.
Levels of cTnI were signiﬁcantly higher in groups 10TP and
10TP+DOX compared to control, which is accompanied
by morphological changes of rat myocardium (Table 2).
Insigniﬁcant change in AST plasma activity was found in all
study groups.
3.4. Proteins SERCA2 and RyR2. SERCA2 protein content
after administration of lower dose of TP with DOX was
signiﬁcantly higher with regard to control and DOX group
(Figure 3). DOX reduces and 5TP increases RYR2 protein
level comparing to the control (Figure 4). In 5TP+DOX
group the level of RYR2 was signiﬁcantly higher versus
DOX group, but there was no diﬀerence compared to the
control. Together, the comparison between groups of DOX
and TP+DOX has shown that both doses of TP increased
RyR2 and lower dose of TP increased SERCA2 concentration
in rats receiving DOX.
4. Discussion
As it was stressed above, the metabolism of TP in normoxic
conditions runs via the same pathways as DOX cardiotoxic-
related mechanisms [16, 19, 20, 25, 26, 28, 29]. It was
assumed that coadministration of both drugs leads to
interaction referring to red-ox status and cardiomyocytes
cytotoxicity. For these reasons the objective of the study was
to assess oxidative stress and cardiomyocyte necrosis in rats
administered TP and DOX simultaneously. Moreover, due to
DOX having disadvantageous eﬀect on RyR2 and SERCA2
[7, 9, 37–39] and the key contractile molecules, the content
of these proteins has been also assessed.
Table 2: Plasma concentrations of cTnI and AST activity.
n cTnI (ng/mL) AST (IU/I)
Control 7 1.14 ± 0.85 112.00 ±24.58
DOX 7 1.98 ± 2.35 158.60 ±151.36
5TP+DOX 7 2.40 ± 2.14 153.40 ±52.76
10TP+DOX 7 2.90 ± 1.06a 149.25 ±49.26
5TP 7 2.40 ± 2,23 107.00 ±13.19
10TP 7 3.11 ± 0.96a 133.0 ±33.83
aP < 0.05 versus control.
The main results of the current study indicate protective
eﬀect of TP on oxidative stress and RyR2 protein level
disturbed by DOX. However, an additive eﬀect referring to
SERCA2 protein level was found when lower dose of TP was
given with DOX. There was no additive eﬀect on cardiomy-
ocytes necrosis when rats were treated with both drugs at the
same time.
As it was highlighted in Section 1, NADPH is used
in one-electron reduction of both studied drugs causing
ROS generation [10, 25–27]. Paradoxically, on the other
hand, NADPH is an indispensable factor in quenching of
ROS by glutathione regeneration mechanism. In the light
of this fact a decrease in NADPH level may be expected.
However, there were no changes in NADPH concentrations
in any groups receiving DOX or TP alone. Moreover, a
signiﬁcant increase was found in 10TP+DOX comparing to
the control and DOX. This observed eﬀect is presumably
a result of adaptation mechanism enabling overproduction
of NADPH, for example, by G6PDH and malic enzymes,
the main cell sources of that factor, in response to oxidative
stress. NADPH-dependent GSH/GSSG ratio is higher not
only in 10TP+DOX but over twofold increase versus control
was found in every tested group. Normal level of NADPH
and at the same time higher GSH/GSSG ratio in the rest of
groups indicate that the physiological capacity of NADPH-
dependent regeneration of GSH is very eﬃcient. The ques-
tion arises why GSH/GSSG ratio is elevated. It was revealed
thatMDA+4HNEconcentrationisalsohigherineverytested
group, and, thus, GSH/GSSG ratio even in higher level is not
enough to quench lipid peroxidation and oxidative stress is
still present even one week after the ﬁnal dose.
Moreover, it has been indicated that lipid peroxidation
in hearts of rats administered with DOX only was fourOxidative Medicine and Cellular Longevity 5
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Figure 2: (a) Increased eosinophilia of scattered cardiomyocytes (10TP+DOX group; H&E, objective magniﬁcation 10x). (b) Positive color
reaction detecting necrosis (group 10TP+DOX; Selye’s method, objective magniﬁcation 20x).
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Figure 3:RepresentativeWesternblotanalysisforSERCA2proteinincardiacmusclehomogenates(beta-actinisshownasaloadingcontrol)
and densitometric analysis (mean ± SD) of total SERCA2 content expressed as percent changes with respect to the control group, which was
established at 100%. aP < 0.05 versus control, bP < 0.05 versus DOX.6 Oxidative Medicine and Cellular Longevity
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Figure 4: Representative Western blot analysis for RyR2 protein in cardiac muscle homogenates (beta-actin is shown as a loading control)
and densitometric analysis (mean ± SD) of total RyR2 content expressed as percent changes with respect to the control group, which was
established at 100%. aP < 0.05 versus control, bP < 0.05 versus DOX.
times higher compared to control. Administration with TP
in animals treated with DOX decreased the level of lipid
peroxidation, which suggests a protective inﬂuence of TP.
The majority of prior researches indicated oxidative stress
symptomswithinshorttimeaftersingle-doseadministration
or last dose application of DOX. Knowing the red-ox
metabolism of DOX, it is possible to assume that while the
drug is still present in the tissue, there will be production of
ROS and oxidative stress, which was evidenced in multiple
studies [23, 42, 43]. Presence of oxidative stress one week
after the last dose of DOX, therefore after the drug has
been removed from the organism, is consistent with another
study [44] and hypothesis explaining late cardiotoxicity of
DOX based on oxidative stress [45, 46]. According to this
hypothesis oxidative damage, formed in the presence of
DOX, is “recorded” and after many years may lead to overt
heart failure. ROS, formed in the presence of DOX, leads
to oxidative mitochondrial DNA (mtDNA) damage [47–49].
These changes can then lead to disturbances in synthesis of
proteins necessary to mitochondrial function, particularly
complexes of electron transport chain metabolism pathways
[50]. This, as a result, leads to an overproduction of ROS
compared to physiologicalconditions. Increasein mitochon-
drial ROS level causes mitochondrial DNA damage and
in this way the cycle of events may repeat itself until the
productivity of mitochondria is ﬁnally limited [51], with
possible subsequent serious implications in tissue with high
metabolic rate. Finally, one can observe contractility distur-
bances and congestive heart failure. It is worth emphasizing
that mitochondria are particularly vulnerable to an inﬂuence
of oxidative stress as previously described [51].
There is abundant evidence proving toxic damage to
mitochondria caused by DOX activity on morphological
[52], biochemical [10, 53, 54], and molecular levels [45,
55, 56]. Additionally, it has also been stated that TP causes
mitochondrial dysfunction [18]. In relation with the above,
the level of NADH, main substrate for the electron transport
chain, has been assessed. There was no signiﬁcant diﬀerence
in NADH level in any of the groups administered DOX
compared to control (DOX, 5TP+DOX, 10TP+DOX); how-
ever, a signiﬁcant increase in NADH level was observed in
10TP+DOX group compared to DOX. Therefore, the groupOxidative Medicine and Cellular Longevity 7
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Figure 5: DNA oxidative damage (AP/100kbp) in heart homoge-
nates. ∗P < 0.05 versus control.
indicating protective inﬂuence of TP (10TP+DOX) at the
same time has also higher NADH level. It is a matter of
discussionifincreasedlevelofNADHisaresultofmitochon-
drial failure or escalated synthesis of the nucleotide itself. It
seems that the ﬁrst interpretation is more probable because
NADHsynthesisisbasedonbeta-oxidationoffattyacidsand
Krebs cycle. Both of these metabolic pathways are hampered
by DOX: beta-oxidation as a result of impediment of long-
chain fatty acids transport [57] and Krebs cycle through
blocking aconitase by superoxide formed in the presence of
DOX [10]. Therefore, it seems that the higher concentration
of NADH observed in group 10TP+DOX may be a result
of cumulative unfavorable actions of both factors towards
the electron transport chain. Considering the alleviating
inﬂuenceofhigherdoseofTPonlipidperoxidationinhearts
of rats treated with DOX, DNA oxidative damage (sum of
mitochondrial and nuclear) has also been assessed in these
groups.Theresultsconﬁrmedthepresenceofoxidativestress
in all evaluated groups; however, there was no interaction
between the studied compounds.
It should also be stressed that the pathomechanism of
contractilitydisturbancesofmyocardiumismultidirectional.
Oxidative stress plays an important role in the process and in
the present study it was assessed based on MDA and oxDNA
levels and was elicited by both compounds. Oxidative stress
through cumulative and mitochondrial dysfunction (escalat-
ing with time) causes depletion in ATP [54, 58] necessary in
the process of myocardial ﬁber contractions. It may also be a
basis for pathological changes in calcium regulation through
proteins RyR2 and SERCA2. Finally, oxidative stress can
lead to myocardial necrosis, remodeling, and contractility
disturbances. In the present study it has been evidenced
that DOX majorly decreases RyR2 protein level. In contrast,
after administering 5TP RyR2 level was over 2.5 times higher
than in control. After increasing the dose of TP (10TP)
RyR2 level was approximately 30% higher than control but
the diﬀerence was not statistically signiﬁcant. TP causes
oxidative stress and simultaneously increases level of RyR2,
which indicates that oxidative stress is not a factor limiting
RyR2 synthesis in spite of disrupting the function of this
protein. Therefore, the decrease in RyR2 level observed in
DOX group does probably not result from oxidative stress. It
maybeexpectedthatadministrationoftwocompoundswith
opposite actions will not elicit changes compared to control.
This thesis is concordant with our observations in both
groups 5TP+DOX and 10TP+DOX. Moreover, RyR2 level in
groups administered DOX and TP was signiﬁcantly higher
when compared to group given DOX only, which suggests
protective inﬂuence of TP on regulation of RyR2 level in
hearts of animals treated with DOX. A RyR2 concentration
decreasewasalsoobservedinotherstudies[40,41]including
our previous study [59] in which the cumulative dose of
DOX was 15mg/kg (1.5 × 10 weeks) and the samples were
obtained three weeks after termination of drug admin-
istration. There was interaction between 5TP and DOX
pertaining to SERCA2 level as SERCA2 level was signiﬁcantly
higher in group 5TP+DOX compared to DOX. It seems this
change may have a negative inﬂuence on cardiomyocytes.
T h e s ea s s u m p t i o n sa r es u p p o r t e db yB u r k ee ta l .[ 60], which
indicated signiﬁcantly lower survival factor in mice with
overexpression of SERCA2 gene treated with DOX as well
as greater degree of histological damages compared to an
isogenic control. There was no interaction between TP and
DOX pertaining to cardiomyocyte necrosis. Observed mor-
phological features of necrosis in group 10TP+DOX should
be understood as TP action because features of necrosis
were similar in groups 10TP and 10TP+DOX. Analogically,
one can interpret cTnI concentration, which conﬁrms the
p r e s e n c eo fc a r d i o m y o c y t en e c r o s i si ng r o u p1 0 T P + D O X .
In summary, the study revealed dose-dependent inter-
action between TP and DOX pertaining to myocardial
oxidative stress and concentration of proteins taking part
in heart muscle contraction. The open question remains if
observed alterations are persistent or if the changes reverse
after longer period of time. For this reason, further studies
with diﬀerent range of time after ﬁnal dose of both drugs are
needed to assess the eﬀect of that interaction on contractility
function of the heart.
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